NASDAQ:EPZM

Epizyme Competitors

$8.22
+0.03 (+0.37 %)
(As of 04/14/2021 04:30 PM ET)
Add
Compare
Today's Range
$8.10
Now: $8.22
$8.46
50-Day Range
$7.45
MA: $8.93
$10.69
52-Week Range
$7.44
Now: $8.22
$22.00
Volume1.09 million shs
Average Volume1.10 million shs
Market Capitalization$836.67 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76

Competitors

Epizyme (NASDAQ:EPZM) Vs. PTCT, ACAD, CCXI, INSM, RETA, and ALKS

Should you be buying EPZM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Epizyme, including PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), ChemoCentryx (CCXI), Insmed (INSM), Reata Pharmaceuticals (RETA), and Alkermes (ALKS).

PTC Therapeutics (NASDAQ:PTCT) and Epizyme (NASDAQ:EPZM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

89.8% of Epizyme shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 16.3% of Epizyme shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares PTC Therapeutics and Epizyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-123.19%-76.10%-24.60%
Epizyme-1,899.35%-83.45%-52.66%

Valuation & Earnings

This table compares PTC Therapeutics and Epizyme's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million10.97$-251,580,000.00($3.45)-13.88
Epizyme$23.80 million35.15$-170,290,000.00($1.93)-4.26

Epizyme has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for PTC Therapeutics and Epizyme, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics05702.58
Epizyme04302.43

PTC Therapeutics currently has a consensus price target of $64.90, indicating a potential upside of 35.52%. Epizyme has a consensus price target of $17.00, indicating a potential upside of 107.06%. Given Epizyme's higher possible upside, analysts plainly believe Epizyme is more favorable than PTC Therapeutics.

Volatility & Risk

PTC Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Epizyme has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Summary

Epizyme beats PTC Therapeutics on 8 of the 14 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Epizyme (NASDAQ:EPZM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares ACADIA Pharmaceuticals and Epizyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Epizyme-1,899.35%-83.45%-52.66%

Analyst Recommendations

This is a summary of current recommendations for ACADIA Pharmaceuticals and Epizyme, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals012702.37
Epizyme04302.43

ACADIA Pharmaceuticals currently has a consensus price target of $32.7647, indicating a potential upside of 54.04%. Epizyme has a consensus price target of $17.00, indicating a potential upside of 107.06%. Given Epizyme's stronger consensus rating and higher possible upside, analysts plainly believe Epizyme is more favorable than ACADIA Pharmaceuticals.

Insider and Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 89.8% of Epizyme shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 16.3% of Epizyme shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

ACADIA Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Epizyme has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Valuation & Earnings

This table compares ACADIA Pharmaceuticals and Epizyme's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million10.04$-235,260,000.00($1.60)-13.30
Epizyme$23.80 million35.15$-170,290,000.00($1.93)-4.26

Epizyme has lower revenue, but higher earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.

Summary

ACADIA Pharmaceuticals beats Epizyme on 8 of the 14 factors compared between the two stocks.

Epizyme (NASDAQ:EPZM) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings & Valuation

This table compares Epizyme and ChemoCentryx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Epizyme$23.80 million35.15$-170,290,000.00($1.93)-4.26
ChemoCentryx$36.13 million91.38$-55,490,000.00($0.98)-48.31

ChemoCentryx has higher revenue and earnings than Epizyme. ChemoCentryx is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Epizyme and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Epizyme-1,899.35%-83.45%-52.66%
ChemoCentryx-58.10%-17.23%-11.07%

Risk & Volatility

Epizyme has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Epizyme and ChemoCentryx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epizyme04302.43
ChemoCentryx01713.00

Epizyme presently has a consensus price target of $17.00, indicating a potential upside of 107.06%. ChemoCentryx has a consensus price target of $80.7778, indicating a potential upside of 70.60%. Given Epizyme's higher possible upside, equities analysts clearly believe Epizyme is more favorable than ChemoCentryx.

Insider and Institutional Ownership

89.8% of Epizyme shares are owned by institutional investors. Comparatively, 80.7% of ChemoCentryx shares are owned by institutional investors. 16.3% of Epizyme shares are owned by company insiders. Comparatively, 9.3% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ChemoCentryx beats Epizyme on 10 of the 15 factors compared between the two stocks.

Epizyme (NASDAQ:EPZM) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Epizyme and Insmed's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Epizyme$23.80 million35.15$-170,290,000.00($1.93)-4.26
Insmed$136.47 million24.99$-254,340,000.00($3.01)-10.97

Epizyme has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Epizyme and Insmed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Epizyme-1,899.35%-83.45%-52.66%
Insmed-145.14%-79.58%-31.14%

Volatility & Risk

Epizyme has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Epizyme and Insmed, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epizyme04302.43
Insmed00703.00

Epizyme presently has a consensus target price of $17.00, indicating a potential upside of 107.06%. Insmed has a consensus target price of $53.8571, indicating a potential upside of 63.15%. Given Epizyme's higher probable upside, research analysts clearly believe Epizyme is more favorable than Insmed.

Insider & Institutional Ownership

89.8% of Epizyme shares are owned by institutional investors. 16.3% of Epizyme shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Epizyme (NASDAQ:EPZM) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Epizyme and Reata Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Epizyme$23.80 million35.15$-170,290,000.00($1.93)-4.26
Reata Pharmaceuticals$26.52 million122.51$-290,170,000.00($9.54)-9.41

Epizyme has higher earnings, but lower revenue than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Epizyme and Reata Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Epizyme-1,899.35%-83.45%-52.66%
Reata Pharmaceuticals-4,340.72%-163.42%-56.49%

Volatility & Risk

Epizyme has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Epizyme and Reata Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epizyme04302.43
Reata Pharmaceuticals00603.00

Epizyme presently has a consensus target price of $17.00, indicating a potential upside of 107.06%. Reata Pharmaceuticals has a consensus target price of $251.25, indicating a potential upside of 180.04%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reata Pharmaceuticals is more favorable than Epizyme.

Insider & Institutional Ownership

89.8% of Epizyme shares are owned by institutional investors. Comparatively, 64.3% of Reata Pharmaceuticals shares are owned by institutional investors. 16.3% of Epizyme shares are owned by company insiders. Comparatively, 31.7% of Reata Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Epizyme beats Reata Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Epizyme (NASDAQ:EPZM) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Epizyme and Alkermes' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Epizyme$23.80 million35.15$-170,290,000.00($1.93)-4.26
Alkermes$1.17 billion2.62$-196,620,000.00$0.07274.71

Epizyme has higher earnings, but lower revenue than Alkermes. Epizyme is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Epizyme and Alkermes' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Epizyme-1,899.35%-83.45%-52.66%
Alkermes-6.28%9.35%5.50%

Volatility & Risk

Epizyme has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Epizyme and Alkermes, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epizyme04302.43
Alkermes16102.00

Epizyme presently has a consensus target price of $17.00, indicating a potential upside of 107.06%. Alkermes has a consensus target price of $20.8571, indicating a potential upside of 8.57%. Given Epizyme's stronger consensus rating and higher probable upside, research analysts clearly believe Epizyme is more favorable than Alkermes.

Insider & Institutional Ownership

89.8% of Epizyme shares are owned by institutional investors. Comparatively, 97.3% of Alkermes shares are owned by institutional investors. 16.3% of Epizyme shares are owned by company insiders. Comparatively, 4.5% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Epizyme beats Alkermes on 8 of the 14 factors compared between the two stocks.


Epizyme Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90+1.2%$3.33 billion$306.98 million-6.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.28+3.2%$3.30 billion$339.08 million-12.37Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.34+0.3%$3.29 billion$36.13 million-70.66Unusual Options Activity
Gap Down
Insmed logo
INSM
Insmed
1.2$33.02+4.1%$3.27 billion$136.47 million-12.70
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.75+3.7%$3.13 billion$26.52 million-7.91
Alkermes logo
ALKS
Alkermes
1.2$19.23+1.9%$3.00 billion$1.17 billion-41.80
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.44+3.8%$3.00 billionN/A-57.43Insider Selling
Gap Down
Arvinas logo
ARVN
Arvinas
1.5$62.89+2.5%$3.00 billion$42.98 million-24.57News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.43+1.7%$2.99 billion$421.03 million24.45Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.69+1.5%$2.94 billion$80.43 million108.05Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80+0.6%$2.77 billion$644.77 million-10.39
OPKO Health logo
OPK
OPKO Health
1.9$4.20+1.7%$2.77 billion$901.90 million-23.33
Organogenesis logo
ORGO
Organogenesis
1.0$21.90+3.7%$2.70 billion$260.98 million-365.00
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.53+3.4%$2.69 billionN/A-23.92
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98+6.7%$2.64 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.95+2.9%$2.61 billion$306.49 million25.79
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27+3.8%$2.51 billion$60,000.00-10.02
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.96+5.5%$2.50 billion$25 million-9.19Insider Selling
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.47+3.1%$2.50 billion$2.11 million-8.98Analyst Report
News Coverage
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$151.03+2.7%$2.44 billion$120.28 million-152.56Analyst Report
Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.9$51.64+1.3%$2.38 billion$33.94 million-89.03
Xencor logo
XNCR
Xencor
1.0$43.17+6.9%$2.33 billion$156.70 million-30.84News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.21+2.3%$2.30 billion$15 million-17.39Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.80+4.5%$2.29 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.81+0.5%$2.20 billion$963.01 million13.61News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.83+3.6%$2.05 billion$23.90 million-17.29Analyst Report
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.11+0.6%$2.01 billion$429.76 million-102.18News Coverage
Gap Down
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.55+3.4%$2.00 billionN/A-19.91
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.17+1.3%$1.98 billion$410,000.00-6.12Analyst Report
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$120.94+4.4%$1.94 billionN/A-10.93
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.65+1.7%$1.92 billion$34.51 million-17.65
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.93+2.6%$1.91 billionN/A-27.20Increase in Short Interest
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$47.01+2.9%$1.87 billionN/A0.00Analyst Report
Gap Down
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.80+5.3%$1.87 billion$103.54 million-19.40Insider Selling
MORF
Morphic
1.3$55.98+3.0%$1.87 billion$16.98 million-35.88Insider Selling
Decrease in Short Interest
News Coverage
Kura Oncology logo
KURA
Kura Oncology
1.6$29.20+5.8%$1.82 billionN/A-17.91Gap Down
FibroGen logo
FGEN
FibroGen
1.8$19.26+2.4%$1.81 billion$256.58 million-7.38Analyst Report
News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$31.28+5.5%$1.77 billion$64.19 million-9.99Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.99+0.1%$1.77 billion$14.87 million-14.18Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.82+1.0%$1.73 billion$1.63 billion14.20Analyst Report
Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.26+1.4%$1.71 billion$26.87 million-12.70Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.63+3.0%$1.66 billion$428.41 million15.41News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$31.87+1.8%$1.66 billion$392.76 million13.22Analyst Upgrade
Analyst Revision
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$29.08+2.1%$1.65 billionN/A0.00Analyst Revision
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.59+1.6%$1.63 billion$320,000.00-8.56Analyst Report
uniQure logo
QURE
uniQure
1.7$34.88+0.0%$1.57 billion$7.28 million-9.25
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$24.34+6.6%$1.57 billion$2.34 million-10.31Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.54+2.7%$1.55 billionN/A-6.24Increase in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.